Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2025-08-12 Report Publication Anno…
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Lifecare ASA (LIFE): Invitation to presentation of Q2 2025 results 20 August at 10.45 CEST
Report Publication Announcement Classification · 1% confidence The document is an invitation to a presentation of Q2 2025 results. It is short (1714 characters), does not contain the actual financial results, and serves as an announcement regarding the timing and access details for an upcoming report and presentation. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-08-12 English
Lifecare receives ethics approval to initiate first-in-human trial in Norway - Attachment: Lifecare receives ethics approval to initiate first-in-human trial in Norway.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by Lifecare ASA announcing that they have received ethics approval for a first-in-human clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it is the primary news release itself. Since it is a general corporate announcement regarding operational progress and regulatory milestones that does not fall into the other specialized categories, it is best classified as a Regulatory Filing (RNS).
2025-08-05 English
Lifecare receives ethics approval to initiate first-in-human trial in Norway
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Lifecare ASA has received ethics approval for a first-in-human clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a dividend or share-related announcement. As it is a general corporate announcement regarding operational progress and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-08-05 English
Lifecare achieves full radio frequency compliance for CGM implant clearing the way for CE mark of electronics - Attachment: Lifecare achieves full radio frequency compliance for CGM implant clearing
Regulatory Filings Classification · 1% confidence The document is a press release from Lifecare ASA dated July 8, 2025, announcing the successful completion of radio frequency (Rf) compliance testing for its CGM implant electronics. It discusses regulatory milestones (CE-marking process), technical achievements (Rf and EMC testing), and future plans (clinical trials). This type of announcement, detailing progress toward regulatory approval and technical validation, does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, DIRS). It is a general corporate update regarding product development and regulatory status. Since it is not a formal financial report, a management discussion, or a specific shareholder action, it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard regulatory/technical update, or potentially a general Investor Relations announcement. Given the focus on regulatory compliance and technical validation, RNS is the most appropriate fallback for a significant, non-scheduled corporate announcement that isn't a core financial filing.
2025-07-08 English
Lifecare achieves full radio frequency compliance for CGM implant clearing the way for CE mark of electronics
Regulatory Filings Classification · 1% confidence The document is a press release dated July 8, 2025, announcing a specific operational milestone: the successful completion of radio frequency (Rf) compliance testing for their Continuous Glucose Monitoring (CGM) implant, which clears the way for CE marking. This announcement details technical progress, regulatory steps (CE-marking, clinical trials), and includes quotes from the CEO. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a DVA or DIRS. Since it is an announcement about a specific development that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or operational news releases that are not explicitly covered elsewhere. Given the nature of the announcement (technical compliance update), RNS is the most appropriate fit among the provided options.
2025-07-08 English
Lifecare advances electromagnetic compatibility compliance testing for CGM implant - Attachment: Lifecare advances electromagnetic compatibility compliance testing for CGM implant.pdf
Regulatory Filings Classification · 1% confidence The document is a press release dated July 1, 2025, announcing the completion of initial Electromagnetic Compatibility (EMC) and Radio Frequency (Rf) testing for their Continuous Glucose Monitoring (CGM) implant electronics. It details a technical milestone, quotes the CEO, and discusses the path toward regulatory compliance (CE-marking) and clinical trials. This type of announcement, focusing on a specific operational or technical update rather than comprehensive financial results (10-K, IR, ER) or management changes (MANG), fits best under a general regulatory or operational update category. Since it is not a formal financial report, a transcript, or a specific legal/governance filing, and it is an announcement of progress, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the testing was tied to funding milestones, but RNS is the best fit for a general operational press release that doesn't match other specific categories.
2025-07-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.